Consun Pharma
Consun Pharma, officially known as China Consun Pharmaceutical Group, is a prominent player in the pharmaceutical industry, headquartered in China (CN). Established in 1995, the company has made significant strides in the development and manufacturing of high-quality pharmaceutical products, primarily focusing on prescription medications and over-the-counter solutions. With a strong operational presence across Asia and expanding into international markets, Consun Pharma is recognised for its commitment to innovation and quality. The company’s core offerings include a diverse range of therapeutic drugs, particularly in the fields of cardiovascular health and anti-infectives, distinguished by their efficacy and safety profiles. Notably, Consun Pharma has achieved several milestones, including certifications from international regulatory bodies, which solidify its market position as a trusted provider in the global pharmaceutical landscape.
DitchCarbon Score
How does Consun Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Consun Pharma's score of 28 is lower than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Consun Pharma's reported carbon emissions
In 2022, Consun Pharma reported total carbon emissions of approximately 72,057,200 kg CO2e. This figure includes 53,214,680 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and 18,842,520 kg CO2e from Scope 2 emissions, related to the consumption of purchased electricity and steam. The company has set ambitious long-term reduction targets, aiming to decrease its combined Scope 1 and 2 greenhouse gas emissions by 54.6% from a 2023 baseline by the year 2033. This commitment reflects a proactive approach to mitigating climate impact and aligns with industry standards for sustainability. Consun Pharma has consistently disclosed its emissions data, with a focus on transparency and accountability. The emissions data for previous years shows a slight increase from 71,151,211.4 kg CO2e in 2021 and a significant rise from 31,857,680 kg CO2e in 2020. The company has not yet reported any Scope 3 emissions, which would include indirect emissions from the value chain. Overall, Consun Pharma's climate commitments and emissions data demonstrate a clear intention to address its environmental footprint while contributing to broader climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 7,978,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Consun Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
